(Q35993536)

11 August 2017

A phase II trial of goserelin (Zoladex) in relapsed epithelial ovarian cancer (English)

1 reference

https://api.crossref.org/works/10.1038/BJC.1992.126

11 August 2017

phase II clinical trial

0 references

1 reference

1 reference

3 December 2023

1 reference

https://api.crossref.org/works/10.1038/BJC.1992.126

3 December 2023

8

A. L. Harris

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1314071

3 December 2023

author name string

M. J. Lind

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1314071

12 September 2022

B. M. Cantwell

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1314071

12 September 2022

M. J. Millward

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1314071

12 September 2022

A. Robinson

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1314071

12 September 2022

M. Proctor

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1314071

12 September 2022

D. Simmons

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1314071

12 September 2022

J. Carmichael

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1314071

12 September 2022

language of work or name

English

0 references

publication date

1 April 1992

1 reference

PMC publication ID

1977567

full work available at URL

11 August 2017

https://europepmc.org/articles/PMC1977567

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1314071

https://europepmc.org/articles/PMC1977567?pdf=render

12 September 2022

file format

Portable Document Format

online access status

open access

content deliverer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1314071

https://www.nature.com/articles/bjc1992126.pdf

12 September 2022

file format

Portable Document Format

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1314071

http://www.nature.com/articles/bjc1992126.pdf

3 December 2023

file format

Portable Document Format

1 reference

https://api.crossref.org/works/10.1038/BJC.1992.126

http://www.nature.com/articles/bjc1992126

3 December 2023

1 reference

https://api.crossref.org/works/10.1038/BJC.1992.126

British Journal of Cancer

3 December 2023

published in

1 reference

11 August 2017

65

1 reference

11 August 2017

4

1 reference

11 August 2017

621-623

1 reference

Ovarian cancer (review). Etiology, diagnosis, prognosis, surgery, radiotherapy, chemotherapy and endocrine therapy

11 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1977567

The use of an LH-RH agonist (ICI 118630, Zoladex) in advanced premenopausal breast cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1977567

Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1977567

Zoladex: endocrine and therapeutic effects in post-menopausal breast cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1977567

Oestrogen receptor expression and the effects of oestrogen and tamoxifen on the growth of human ovarian carcinoma cell lines

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1977567

Plasma level of estradiol in patients with ovarian malignant tumors.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1977567

Treatment of advanced refractory ovarian carcinoma with a gonadotropin-releasing hormone analogue.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1977567

Leuprolide acetate in the treatment of refractory or persistent epithelial ovarian cancer

11 July 2018

1 reference

12 December 2020

Gonadotropin releasing hormone binding sites in human epithelial ovarian carcinomata

1 reference

12 December 2020

Correlation between tumor histology, steroid receptor status, and adenosine deaminase complexing protein immunoreactivity in ovarian cancer

1 reference

12 December 2020

Suppression of postmenopausal ovarian steroidogenesis with the luteinizing hormone-releasing hormone agonist goserelin

1 reference

12 December 2020

The definition of the ‘no change’ category in patients treated with endocrine therapy and chemotherapy for advanced carcinoma of the breast

1 reference

12 December 2020

Identifiers

DOI

10.1038/BJC.1992.126

1 reference

11 August 2017

1 reference

PMC publication ID

1977567

11 August 2017

1 reference

PMC publication ID

1977567